Mucosal Immune Defence Research Stack
Reviewed by the BestHealingPeptides Editorial Team ·
Address the three mechanistic axes of mucosal defence — anti-inflammatory cytokine suppression, antimicrobial peptide activity, and tight-junction barrier integrity — in pre-clinical gut-immunity models.
Components
Protocol notes
All three peptides have distinct delivery requirements. KPV is typically encapsulated for colonic delivery (hyaluronic-acid nanoparticles being the established platform from the Laroui et al. 2013 work). LL-37 is parenterally or topically delivered in research models; oral LL-37 is rapidly degraded. Larazotide is designed for oral luminal delivery with minimal systemic absorption. Combined-arm protocols therefore require multiple delivery routes per animal, which complicates study design but is unavoidable given the pharmacology.
Mechanistic rationale
KPV (the C-terminal Lys-Pro-Val tripeptide of α-MSH) suppresses NF-κB-driven inflammatory cytokine release in mucosal cells — TNF-α, IL-1β, IL-6 — through intracellular pathway interaction independent of melanocortin receptor signalling. LL-37 provides direct broad-spectrum antimicrobial activity against gut pathogens (Pseudomonas aeruginosa, Salmonella, pathogenic E. coli) alongside FPR2-mediated chemotaxis of immune cells to the mucosal surface; cathelicidin deficiency is documented in inflammatory bowel disease and provides a clear rationale for supplementation research. Larazotide restores tight-junction integrity through zonulin-receptor antagonism, limiting paracellular passage of luminal antigens that drive the inflammatory cascade in coeliac disease and other barrier-disruption phenotypes. The three together cover the inflammatory, antimicrobial, and barrier-integrity axes of mucosal pathology.
Endpoint suggestions
Mucosal endpoints: histological scoring (Wallace, Geboes) of colon; faecal calprotectin (or its rodent equivalents); tissue cytokine panels (TNF-α, IL-1β, IL-6, IL-10, IL-17, IFN-γ). Barrier endpoints: lactulose/mannitol urinary ratio for intestinal permeability; serum LPS as a translocation marker; tight-junction protein (ZO-1, occludin, claudin-1) localisation by immunofluorescence. Microbial endpoints: 16S rRNA sequencing of caecal/colonic contents; pathogen colony counts in challenge models. Systemic immune endpoints: spleen cytokine production after ex-vivo stimulation; regulatory T-cell frequency in mesenteric lymph nodes.
Confounders
Microbiome variability is the dominant confounder in mucosal-immunity models. Housing conditions (cage, bedding, water source), diet composition, and supplier-of-origin all influence baseline microbiota and immune tone. Animals should be cohoused or littermate-controlled. The colitis-induction model (DSS dose, TNBS protocol) selection materially affects which mechanistic readouts are most informative. Vehicle pH must be controlled — KPV nanoparticle encapsulation is pH-sensitive, and gastric acidity rapidly inactivates unencapsulated LL-37.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.